Bio-Rad Laboratories Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
16
Price Target
$582.50
Consensus
Outperform
Upside
23.70%
Analysts
0
Stock Rating
16
Upside
23.70%
Analysts
0
Price Target
$582.50

Bio-Rad Laboratories Stock Forecast and Price Target

Year-long price target forecasts from prominent analysts have recently been released for Bio-Rad Laboratories, with an average price target of $582.50. This potential gain of 23.7 percent from the previous closing price in February, 2023 is calculated on a high forecast of $640.00 and a low estimate of $550.00. If you're thinking of investing in BIO stock, it might be good to look at its rivals too.

$582.50

23.70% Upside

Buy
Buy

Bio-Rad Laboratories Fair Value Forecast for 2023 - 2025 - 2030

Bio-Rad Laboratories's Price has grown in the last two years, jumping from $330.48 to $733.04 – an increase of 121.81%. The next year, 0 experts forecast that Bio-Rad Laboratories's Fair Value will decrease by 32.84%, reaching $492.29. In 2030, professionals predict that Bio-Rad Laboratories's Fair Value will decrease by 26.15%, reaching $541.38.

2022 Fair Value Forecast
$492.29
2023 Fair Value Forecast
$464.72
2024 Fair Value Forecast
$498.83
2025 Fair Value Forecast
$578.64
2026 Fair Value Forecast
$550.29
2027 Fair Value Forecast
$521.90
2028 Fair Value Forecast
$516.33
2029 Fair Value Forecast
$536.41
2030 Fair Value Forecast
$541.38
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 11
$164.61 $181.05 9.65%
ROG Stock Forecast Roche Holding Outperform 5
CHF293.60 CHF384.23 24.32%
AVGO Stock Forecast Broadcom Outperform 9
$597.62 $654.63 10.27%
TMO Stock Forecast Thermo Fisher Scientific Inc Outperform 10
$587.76 $618.99 5.49%
DHR Stock Forecast Danaher Corp Outperform 10
$269.85 $304.24 12.84%

Bio-Rad Laboratories Revenue Forecast for 2023 - 2025 - 2030

Bio-Rad Laboratories's Revenue has grown in the last two years, jumping from $2.31B to $2.92B – an increase of 26.43%. The next year, 0 experts forecast that Bio-Rad Laboratories's Revenue will decrease by 11.66%, reaching $2.58B. In 2030, professionals predict that Bio-Rad Laboratories's Revenue will decrease by 10.57%, reaching $2.61B.

2022 Rev Forecast
$2.58B
2023 Rev Forecast
$2.51B
2024 Rev Forecast
$2.53B
2025 Rev Forecast
$2.66B
2026 Rev Forecast
$2.64B
2027 Rev Forecast
$2.59B
2028 Rev Forecast
$2.57B
2029 Rev Forecast
$2.60B
2030 Rev Forecast
$2.61B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ABT Stock Forecast Abbott Laboratories Outperform 10
$111.79 $120.97 11.82%
SIE Stock Forecast Siemens Outperform 6
145.02€ 156.55€ 6.88%
6758 Stock Forecast Sony Group Buy 3
¥10.64k ¥0.00 41.98%

Bio-Rad Laboratories Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 10
185.90€ 209.03€ 12.96%
GE Stock Forecast General Electric Outperform 9
$81.96 $86.47 6.15%
BDX Stock Forecast Becton, Dickinson and Outperform 17
$245.84 $268.00 11.86%

Bio-Rad Laboratories Free Cash Flow Forecast for 2023 - 2025 - 2030

Bio-Rad Laboratories's Free Cash Flow has increased by 49.07% In the last two years, going from $359.37M to $535.72M. According to 0 prominent analysts, Bio-Rad Laboratories's Free Cash Flow will fall by 15.54% in the next year, reaching $452.45M. By 2030, professionals believe that Bio-Rad Laboratories's Free Cash Flow will decrease by 13.64%, reaching $462.64M – a concerning trend for the company.

2022 FCF Forecast
$0.45B
2023 FCF Forecast
$0.43B
2024 FCF Forecast
$0.45B
2025 FCF Forecast
$0.48B
2026 FCF Forecast
$0.47B
2027 FCF Forecast
$0.45B
2028 FCF Forecast
$0.45B
2029 FCF Forecast
$0.46B
2030 FCF Forecast
$0.46B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MMM Stock Forecast 3M Hold 16
$117.49 $147.79 1.71%
SHL Stock Forecast Siemens Healthineers Outperform 18
54.04€ 61.61€ 7.33%
BAYN Stock Forecast Bayer Outperform 7
56.68€ 74.54€ 33.20%

Bio-Rad Laboratories Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Bio-Rad Laboratories's Net Income has grown, increasing from $1.76B to $4.25B – an increase of 141.43%. For the next year, 0 analysts project Bio-Rad Laboratories's Net Income to drop by 24.83%, reaching $3.19B. By 2030, professionals believe that Bio-Rad Laboratories's Net Income will decrease by 20.48%, reaching $3.38B – a concerning trend for the company.

2022 NI Forecast
$3.19B
2023 NI Forecast
$2.86B
2024 NI Forecast
$3.19B
2025 NI Forecast
$3.55B
2026 NI Forecast
$3.45B
2027 NI Forecast
$3.25B
2028 NI Forecast
$3.23B
2029 NI Forecast
$3.34B
2030 NI Forecast
$3.38B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
A Stock Forecast Agilent Technologies Outperform 17
$154.55 $162.50 7.73%
LONN Stock Forecast Lonza Group Ltd Outperform 16
CHF457.90 CHF756.46 71.98%
ILMN Stock Forecast Illumina Inc Outperform 16
$214.26 $254.08 16.45%

Bio-Rad Laboratories EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Bio-Rad Laboratories's EBITDA has grown, increasing from $387.06M to $687.93M – a growth of 77.73%. In the following year, 0 experts forecast Bio-Rad Laboratories's EBITDA will decrease by 23.41%, to $526.86M. In 2030, professionals predict that Bio-Rad Laboratories's EBITDA will decrease by 19.73%, to $552.18M.

2022 EBITDA Forecast
$0.53B
2023 EBITDA Forecast
$0.49B
2024 EBITDA Forecast
$0.52B
2025 EBITDA Forecast
$0.58B
2026 EBITDA Forecast
$0.56B
2027 EBITDA Forecast
$0.54B
2028 EBITDA Forecast
$0.53B
2029 EBITDA Forecast
$0.55B
2030 EBITDA Forecast
$0.55B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
7751 Stock Forecast Canon Hold 18
¥2.86k ¥0.00 16.95%
HOLX Stock Forecast Hologic Inc Outperform 8
$84.68 $79.86 -2.57%
SGSN Stock Forecast SGS Hold 18
CHF2.25k CHF2.84k 27.06%

Bio-Rad Laboratories EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Bio-Rad Laboratories's EBIT has grown by 119.14%, from $252.86M to $554.13M. According to 0 major analysts, Bio-Rad Laboratories's EBIT will fall by 30.20% in the next year, reaching $386.78M. Professionals believe that By 2030, Bio-Rad Laboratories's EBIT will fall to $419.02M– a 24.38% decrease from its current value.

2022 EBIT Forecast
$0.39B
2023 EBIT Forecast
$0.36B
2024 EBIT Forecast
$0.39B
2025 EBIT Forecast
$0.45B
2026 EBIT Forecast
$0.43B
2027 EBIT Forecast
$0.40B
2028 EBIT Forecast
$0.40B
2029 EBIT Forecast
$0.41B
2030 EBIT Forecast
$0.42B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
DGX Stock Forecast Quest Diagnostics Hold 10
$142.81 $147.77 1.18%
PKI Stock Forecast PerkinElmer Outperform 16
$138.56 $159.83 17.28%
ERF Stock Forecast Eurofins Scientific Hold 18
66.16€ 0.00€ 58.71%

Bio-Rad Laboratories EPS Price Prediction Forecast for 2023 - 2025 - 2030

Bio-Rad Laboratories's EPS has grown in the last two years, jumping from $7.06 to $15.66 – an increase of 121.81%. The next year, 0 experts forecast that Bio-Rad Laboratories's EPS will decrease by 32.84%, reaching $10.52. In 2030, professionals predict that Bio-Rad Laboratories's EPS will decrease by 26.15%, reaching $11.57.

2022 EPS Forecast
$10.52
2023 EPS Forecast
$9.93
2024 EPS Forecast
$10.66
2025 EPS Forecast
$12.36
2026 EPS Forecast
$11.76
2027 EPS Forecast
$11.15
2028 EPS Forecast
$11.03
2029 EPS Forecast
$11.46
2030 EPS Forecast
$11.57
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
TECH Stock Forecast Bio-Techne Buy 16
$79.16 $485.91 31.06%
BVI Stock Forecast Bureau Veritas Outperform 18
25.46€ 27.85€ 9.98%
BIM Stock Forecast bioMérieux Outperform 18
96.70€ 105.55€ 11.17%